1
Overview of CDER Nanotechnology-related Drug Database
Nakissa Sadrieh, Ph.D.
Director, Cosmetics Staff, OCAC/CFSAN/FDA
(Previously, Associate Director for Research Policy and Implementation, OPS/CDER/FDA)
FDA/PQRI workshop 2014
Nanotechnology-related Drug Database Nakissa Sadrieh, Ph.D. - - PowerPoint PPT Presentation
Overview of CDER Nanotechnology-related Drug Database Nakissa Sadrieh, Ph.D. Director, Cosmetics Staff, OCAC/CFSAN/FDA (Previously, Associate Director for Research Policy and Implementation, OPS/CDER/FDA) FDA/PQRI workshop 2014 1 What has
1
(Previously, Associate Director for Research Policy and Implementation, OPS/CDER/FDA)
FDA/PQRI workshop 2014
2
– CDER MAPP
– CDER nanotechnology drug database
– Dermal penetration of nanoscale TiO2 in sunscreens. – Development of discriminating dissolution methods for nanocrystals with different particle sizes. – Inhalation toxicology of spray sunscreens and cosmetics.
3
4
5 Nanotechnology Product MaPP Attachment A
1) This review contains new information added to the table below: _______Yes _______No Review date: _____________ 2) Are any nanoscale materials included in this application? (If yes, please proceed to the next questions.) Yes______; No______ ; Maybe (please specify)____________________ 3 a) What nanomaterial is included in the product? (please refer to attachment B for examples of nanomaterial)_______________________________________________________________ 2 b) What is the source of the nanomaterial?________________________________________ 4) Is the nanomaterial a reformulation of a previously approved product? Yes_________ No_________ 5) What is the nanomaterial functionality? Carrier_________________; Excipient__________________; Packaging________________ API____________________; Other____________________ ____________________________________________________________________________ 6) Is the nanomaterial soluble (e.g., nanocrystal) or insoluble (e.g., gold nanoparticle) in an aqueous environment? Soluble __________________; Insoluble___________________ 7) Was nanomaterial particle size or size range included in the application? No_______(please go to 9); Yes________ (please complete 8). 8) What is the reported particle size? Mean particle size___________ ; Size range distribution___________; Other___________________, 9) Please indicate the reason(s) why the particle size or size range was not provided: ____________________________ ____________________________ 10) What other properties of the nanoparticle were reported in the application (See Attachment E)? ____________________________ 11) List all methods used to characterize the nanomaterial? ___________________________
6
aspect of the drug (such as targeted drug delivery, pharmacokinetic profile, a more convenient dosage form thus better patient compliance).
7
52 39 14 9 6 4 3 1 128 10 4 8 2 5 1 30 20 40 60 80 100 120 140 L i p
e s ( 6 2 ) N a n
a r t i c l e s ( 4 3 ) N a n
r y s t a l s ( 2 2 ) M i c e l l e s ( 1 1 ) S P I O ( 1 1 ) N a n
m u l s i
s ( 5 ) C
l
d a l m e t a l s ( 3 ) D e n d r i m e r ( 1 ) A l l ( 1 5 8 ) # of Submissions IND applications
8
Liposomes 39.2% Nanoparticles 27.2% Nanocrystals 13.9% Micelles 7.0% SPIO 7.0% Nanoemulsions 3.2% Colloidal metals 1.9% Dendrimer 0.6%
9
Cancer 38.0% Pain 10.1% Infection 8.9% MRI 5.7% Immunosupp 4.4% Diabetes 3.8% Anemia 3.8% Cholesterol 3.2% Others 22.2%
10
68 51 9 73 91 40 33 1 00 56 1 8 5 9 9 1 8 28 82 9 33 23 7 9 60 4 6 9 9 33 6
20 40 60 80 100 Liposomes (62) Nanoparticles (43) Nanocrystals (22) Micelles (11) SPIO (11) Nanoemulsions (5) Colloidal metals (3) Dendrimer (1) All (158) % Submissions IV Inhalation
topical
11
12
13
1 2 1 9 7 5 4 1 48 35 1 6 6 6 6 4 2 1 76 8 2 1 1 1 2 7 1 1 1 1 29 3 3
10 20 30 40 50 60 70 80 L i p
e s ( 6 5 ) N a n
a r t i c l e ( 4 7 ) N a n
r y s t a l s ( 2 4 ) M i c e l l e ( 1 2 ) S P I O ( 1 1 ) N a n
m u l s i
s ( 5 ) C
l
d a l m e t a l s ( 3 ) D e n d r i m e r ( 1 ) A l l ( 1 6 8 ) # of Submissions Mean Mean range Mean +/- STD Cumulative Not available
14
– Mean, mean range, mean+/-SD, median
15
98% 2% Size available (155) Size not available (3)
16
Dynamic light scattering 24% Laser diffraction 10% Microscopy 6% Cascade Impactor 3%
2% NA 55%
17
35 29 8 26 2 10 20 30 40 50 60
<100 (56) 100 - 300 (46) 300 - 600 (12) 600 - 1000 (0) >1000 (41) NA (3) nm % Submissions
18
49 40 11 10 20 30 40 50 60
<100 (56) 100 - 300 (46) 300 - 600 (12) 600 - 1000 (0) nm % Submissions
19
100 200 300 400 500 600 700 1 2 3 4 5 6 7 8 nm
Liposomes Nanoparticles Nanocrystals Micelles SPIO Nanoemulsions Colloidal Metals
Examples of Biological Responses Subject To Size Limitations
Biological responses Size limits Comments
Glomerular filtration 5-10 nm Physiologic upper limit by renal clearance Nanoparticles transport through liver sinusoid 300 nm Liver fenestrae act as a sieve plate and can control the passage of nanoparticles, allowing only those particles smaller than the fenestrae to reach the liver cells. Size distribution of sinusoidal fenestrae among different species; 75 - 300 nm in rats, 45 - 255 nm in rabbits, 55 - 320 nm in mice and 50 - 300 in humans. Particle shapes and rigidity may further affect the size limit, for example, liposome sizes of up to 400 nm were able to cross the liver fenestrae. Enhanced permeability and retention (EPR) 300-600 nm EPR effects may vary depending on the species, tumor implantation sites and tumor
particles up to 300 nm in diameter extravasate through leaky tumor vasculature and selectively accumulate in tumor tissue via EPR effect. In study involving liposomes, sizes up to 600 nm in diameter were able to permeate through the tissues. Thus, average pore sizes may be approximately assumed in 300 - 600 nm range. Reticuloendothelial system (RES) uptake 300 nm Nanoparticles are cleared by size dependent phagocytosis by the cells in reticuloendothelial system. Extended blood residence time for surface modified nanoparticles up to 200 – 300 nm.
21
22
23
24